Manuela Arcamone

⁹⁰Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial

Christian W. Scholz, Werner Linkesch, Ola Lindén et al. · Journal of Clinical Oncology · 2012 · 108 citations · Full text

Medicine, Hematology, Oncology +16

RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma

Gaetano Corazzelli, Ferdinando Frigeri, Filippo Russo et al. · British Journal of Haematology · 2011 · 77 citations

Medicine, Oncology, Pharmacotherapy +17

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone et al. · Cancer Chemotherapy and Pharmacology · 2009 · 76 citations

Medicine, Oncology, Pharmacology +14

Efficacy and safety of bendamustine for the treatment of patients with recurring <scp>H</scp>odgkin lymphoma

Gaetano Corazzelli, F. Angrilli, Alfonso Maria D’Arco et al. · British Journal of Haematology · 2012 · 63 citations · Full text

Medicine, Oncology, Pharmacology +14

Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone et al. · British Journal of Haematology · 2011 · 58 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +10